Â
Latest Obesity Management Companies Update
Nutrisystem acquired South Beach Diet, expanding its product portfolio and reach in the weight management market.
Novo Nordisk A/S partnered with Weight Watchers International, Inc. to develop and deploy digital therapeutics platforms for obesity management, combining medication and behavioral change programs.
Teladoc Health acquired Livongo Health, Inc., strengthening its digital health offerings and capabilities in chronic disease management, including obesity.
Eli Lilly and Company Received FDA approval for tirzepatide (Mounjaroâ„¢), a first-in-class dual GLP-1 and GIP receptor agonist, offering promising weight loss results with potential to revolutionize obesity treatment.
Amgen launched Iberdureâ„¢ (romosozumab-hvhc), a bone anabolic agent with potential benefits for weight management in patients with obesity and sarcopenia (muscle loss).
Abbott Laboratories Expanded its FreeStyle Libre® 3 glucose monitoring system to include weight tracking and body composition analysis features, aiming to provide a more holistic approach to weight management.
List of Obesity Management Key Companies in the Market
-
Pfizer Inc. (US)
-
F. Hoffmann-La Roche Ltd (Switzerland)
-
GlaxoSmithKline plc. (UK)
-
AstraZeneca (UK)
-
Herbalife Ltd. (US)
-
Apollo Endosurgery (US)
-
Ethicon, Inc. (US)
-
Takeda Pharmaceutical Company (Japan)
-
VIVUS Inc. (US)
-
Currax Pharmaceuticals LLC (US)